GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (STU:698) » Definitions » Additional Paid-In Capital

Achilles Therapeutics (STU:698) Additional Paid-In Capital : €383.27 Mil(As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Additional Paid-In Capital?


Achilles Therapeutics's quarterly additional paid-in capital declined from Sep. 2023 (€387.75 Mil) to Dec. 2023 (€380.75 Mil) but then increased from Dec. 2023 (€380.75 Mil) to Mar. 2024 (€383.27 Mil).

Achilles Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€355.61 Mil) to Dec. 2022 (€385.95 Mil) but then declined from Dec. 2022 (€385.95 Mil) to Dec. 2023 (€380.75 Mil).


Achilles Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Achilles Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Additional Paid-In Capital Chart

Achilles Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
106.16 193.11 355.61 385.95 380.75

Achilles Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 383.41 380.46 387.75 380.75 383.27

Achilles Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Achilles Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Achilles Therapeutics (STU:698) Business Description

Traded in Other Exchanges
Address
245 Hammersmith Road, London, GBR, W6 8PW
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics (STU:698) Headlines

No Headlines